ABBV,REFILE-UPDATE 7-Obama's inversion curbs kill Pfizer's $160 bln Allergan dealObama's inversion curbs kill Pfizer's $160 billion Allergan dealUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule change April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.  UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule change April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes. NEW YORK U.S. drug maker Pfizer Inc agreed on Tuesday to terminate its $160 billion agreement to acquire Botox maker Allergan Plc, in a major victory to U.S. President Barack Obama's drive to stop tax-dodging corporate mergers.UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule change April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.   Obama's inversion curbs kill Pfizer's $160 billion Allergan dealUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule change April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.  UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule change April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes. NEW YORK U.S. drug maker Pfizer Inc agreed on Tuesday to terminate its $160 billion agreement to acquire Botox maker Allergan Plc, in a major victory to U.S. President Barack Obama's drive to stop tax-dodging corporate mergers.UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule change April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.  NEW YORK, April 5 U.S. drug maker Pfizer Inc  agreed on Tuesday to terminate its $160 billion agreement to acquire Botox maker Allergan Plc, in a major victory to U.S. President Barack Obama's drive to stop tax-dodging corporate mergers.Obama's inversion curbs kill Pfizer's $160 billion Allergan dealUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule change April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.  UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule change April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes. NEW YORK U.S. drug maker Pfizer Inc agreed on Tuesday to terminate its $160 billion agreement to acquire Botox maker Allergan Plc, in a major victory to U.S. President Barack Obama's drive to stop tax-dodging corporate mergers.UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule change April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.   
ALK,Airlines in Asia could get a lift from Alaska-Virgin merger April 5 Alaska Air Group Inc's plan to buy Virgin America Inc makes the company a more attractive partner to Asian airlines looking for extra revenue from connecting passengers to flights within the United States, industry executives and experts say. 
AGN,Democratic White House hopefuls cheer end of Pfizer, Allergan dealUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million        UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million         US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million        UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million        Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's  $160 billion merger with Ireland-based Allergan Plc .US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million        UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million       Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a Q2 wake-up for merger-arb hedge fundsMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million      Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     LONDON, April 6 Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer and Allergan - although the effects could have been even worse.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million     US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million    US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million   BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  * Indexes up: Dow 0.64 pct, S&P; 1.05 pct, Nasdaq 1.59 pct   (Updates to close)BRIEF-Moody's confirms Allergan's Baa3 rating outlook stableBRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million  BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million * Baa3 rating reflects allergan's significant scale and good diversity by therapeutic area and product  Source text for Eikon:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Allergan's and Heptares's units enter licensing agreement * Under terms of agreement, Heptares will receive an upfront payment of $125 million         
AMZN,Amazon chief Bezos defends corporate culture in letter to shareholdersDaimler confirms HERE in talks with Amazon, MicrosoftDaimler confirms HERE in talks with Amazon, MicrosoftAmazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  BERLIN Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler said on Wednesday.Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.    Daimler confirms HERE in talks with Amazon, MicrosoftAmazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  BERLIN Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler said on Wednesday.Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   BERLIN, April 6 Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler  said on Wednesday.Daimler confirms HERE in talks with Amazon, MicrosoftAmazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  BERLIN Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler said on Wednesday.Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.     Daimler confirms HERE in talks with Amazon, MicrosoftDaimler confirms HERE in talks with Amazon, MicrosoftAmazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  BERLIN Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler said on Wednesday.Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.    Daimler confirms HERE in talks with Amazon, MicrosoftAmazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  BERLIN Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler said on Wednesday.Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   BERLIN, April 6 Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler  said on Wednesday.Daimler confirms HERE in talks with Amazon, MicrosoftAmazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  BERLIN Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler said on Wednesday.Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.    SAN FRANCISCO, April 5 In a letter sent to shareholders on Tuesday, Amazon.com Inc's founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.Daimler confirms HERE in talks with Amazon, MicrosoftDaimler confirms HERE in talks with Amazon, MicrosoftAmazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  BERLIN Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler said on Wednesday.Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.    Daimler confirms HERE in talks with Amazon, MicrosoftAmazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  BERLIN Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler said on Wednesday.Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   BERLIN, April 6 Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler  said on Wednesday.Daimler confirms HERE in talks with Amazon, MicrosoftAmazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.   Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  BERLIN Amazon.com and Microsoft are in talks about taking a minority stake in HERE, a digital mapping business controlled by Germany's luxury carmakers to help develop self-driving cars, Daimler said on Wednesday.Amazon chief Bezos defends corporate culture in letter to shareholdersUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.  UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. SAN FRANCISCO In a letter sent to shareholders on Tuesday, Amazon.com Inc's  founder and chief executive, Jeff Bezos, defended the online retailer's corporate culture, which was the subject of a critical report by The New York Times last year.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.     
AMT,BRIEF-India clears 51 pct stake sale in Viom Networks to American Tower CorpAmerican Tower to invest $2 bln more in India-telecoms minister NEW DELHI, April 6 American Tower Corp  has committed to invest $2 billion in India, in addition to the 58.57 billion rupees ($879 million) it will spend to acquire a controlling stake in Viom Networks Ltd, the country's telecom minister said on Wednesday.  American Tower to invest $2 bln more in India-telecoms minister NEW DELHI, April 6 American Tower Corp  has committed to invest $2 billion in India, in addition to the 58.57 billion rupees ($879 million) it will spend to acquire a controlling stake in Viom Networks Ltd, the country's telecom minister said on Wednesday. April 6 India cabinet clears 51 percent stake sale in Viom Networks to American Tower Corp  Source text for Eikon:  Further company coverage:    (Reporting by Rajesh Kumar Singh)American Tower to invest $2 bln more in India-telecoms minister NEW DELHI, April 6 American Tower Corp  has committed to invest $2 billion in India, in addition to the 58.57 billion rupees ($879 million) it will spend to acquire a controlling stake in Viom Networks Ltd, the country's telecom minister said on Wednesday.  
BHI,US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  
BAC,MOVES-Bank of America appoints Andrei Magasiner as treasurer April 5 Bank of America Corp on Tuesday appointed Andrei Magasiner as treasurer, replacing Greg Hackworth who is retiring, according to a source familiar with the matter. 
BA,Eleven Boeing workers arrested in South Carolina for tax evasionEleven Boeing workers arrested in South Carolina for tax evasion Eleven Boeing Co employees have been arrested in South Carolina for allegedly attempting to evade state income taxes, and the state's revenue department said more arrests were likely.  Eleven Boeing workers arrested in South Carolina for tax evasion Eleven Boeing Co employees have been arrested in South Carolina for allegedly attempting to evade state income taxes, and the state's revenue department said more arrests were likely. April 6 Eleven Boeing Co employees have been arrested in South Carolina for allegedly attempting to evade state income taxes, and the state's revenue department said more arrests were likely.Eleven Boeing workers arrested in South Carolina for tax evasion Eleven Boeing Co employees have been arrested in South Carolina for allegedly attempting to evade state income taxes, and the state's revenue department said more arrests were likely.  
CVX,Australia's Gorgon LNG plant to restart within 30-60 days -ChevronUPDATE 2-Australia's Gorgon LNG export plant to restart within 30-60 days - ChevronMarubeni, Engie eye bids for Chevron's $3 bln Asia geothermal assets-sourcesReuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   SINGAPORE, April 6 French power and gas group Engie and Japan's Marubeni are among several suitors preparing to bid for Chevron Corp's Asian geothermal energy blocks valued at about $3 billion, sources familiar with the matter said.Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico     Marubeni, Engie eye bids for Chevron's $3 bln Asia geothermal assets-sourcesReuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   SINGAPORE, April 6 French power and gas group Engie and Japan's Marubeni are among several suitors preparing to bid for Chevron Corp's Asian geothermal energy blocks valued at about $3 billion, sources familiar with the matter said.Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    * Gorgon's 1st export cargo delivered at destination in JapanMarubeni, Engie eye bids for Chevron's $3 bln Asia geothermal assets-sourcesReuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   SINGAPORE, April 6 French power and gas group Engie and Japan's Marubeni are among several suitors preparing to bid for Chevron Corp's Asian geothermal energy blocks valued at about $3 billion, sources familiar with the matter said.Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico      UPDATE 2-Australia's Gorgon LNG export plant to restart within 30-60 days - ChevronMarubeni, Engie eye bids for Chevron's $3 bln Asia geothermal assets-sourcesReuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   SINGAPORE, April 6 French power and gas group Engie and Japan's Marubeni are among several suitors preparing to bid for Chevron Corp's Asian geothermal energy blocks valued at about $3 billion, sources familiar with the matter said.Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico     Marubeni, Engie eye bids for Chevron's $3 bln Asia geothermal assets-sourcesReuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   SINGAPORE, April 6 French power and gas group Engie and Japan's Marubeni are among several suitors preparing to bid for Chevron Corp's Asian geothermal energy blocks valued at about $3 billion, sources familiar with the matter said.Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    * Gorgon's 1st export cargo delivered at destination in JapanMarubeni, Engie eye bids for Chevron's $3 bln Asia geothermal assets-sourcesReuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   SINGAPORE, April 6 French power and gas group Engie and Japan's Marubeni are among several suitors preparing to bid for Chevron Corp's Asian geothermal energy blocks valued at about $3 billion, sources familiar with the matter said.Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico     SINGAPORE, April 6 Australia's Gorgon liquefied natural gas (LNG) export terminal is expected to resume production within 30 to 60 days after the facility halted output earlier this month due to mechanical problems, operator Chevron  said on Wednesday.UPDATE 2-Australia's Gorgon LNG export plant to restart within 30-60 days - ChevronMarubeni, Engie eye bids for Chevron's $3 bln Asia geothermal assets-sourcesReuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   SINGAPORE, April 6 French power and gas group Engie and Japan's Marubeni are among several suitors preparing to bid for Chevron Corp's Asian geothermal energy blocks valued at about $3 billion, sources familiar with the matter said.Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico     Marubeni, Engie eye bids for Chevron's $3 bln Asia geothermal assets-sourcesReuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   SINGAPORE, April 6 French power and gas group Engie and Japan's Marubeni are among several suitors preparing to bid for Chevron Corp's Asian geothermal energy blocks valued at about $3 billion, sources familiar with the matter said.Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    * Gorgon's 1st export cargo delivered at destination in JapanMarubeni, Engie eye bids for Chevron's $3 bln Asia geothermal assets-sourcesReuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico    Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   SINGAPORE, April 6 French power and gas group Engie and Japan's Marubeni are among several suitors preparing to bid for Chevron Corp's Asian geothermal energy blocks valued at about $3 billion, sources familiar with the matter said.Reuters Business News Schedule at 1230 GMT/0830 AM ETDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico   Deals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  Pfizer and Allergan scrap $160 bln deal after U.S. pushes tax ruleDeals of the day- Mergers and acquisitionsBRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico  BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico April 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:BRIEF-MRC Global expands service to Chevron into the Gulf of Mexico * MRC Global expands service to Chevron into the gulf of Mexico      
STZ,BRIEF-Constellation Brands agrees to buy Prisoner Wine Company's portfolio of brands from Huneeus VintnersUPDATE 3-Constellation considers IPO for part of Canadian wine business * Shares rise as much as 4.88, touch record high   (Adds analyst comment; updates shares)  UPDATE 3-Constellation considers IPO for part of Canadian wine business * Shares rise as much as 4.88, touch record high   (Adds analyst comment; updates shares) * Agreed to acquire Prisoner Wine Company's portfolio of brands from Huneeus VintnersUPDATE 3-Constellation considers IPO for part of Canadian wine business * Shares rise as much as 4.88, touch record high   (Adds analyst comment; updates shares)  
DAL,Airlines in Asia could get a lift from Alaska-Virgin mergerAirlines in Asia could get a lift from Alaska-Virgin mergerUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   Alaska Air Group Inc's  plan to buy Virgin America Inc  makes the company a more attractive partner to Asian airlines looking for extra revenue from connecting passengers to flights within the United States, industry executives and experts say.United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.     Airlines in Asia could get a lift from Alaska-Virgin mergerUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   Alaska Air Group Inc's  plan to buy Virgin America Inc  makes the company a more attractive partner to Asian airlines looking for extra revenue from connecting passengers to flights within the United States, industry executives and experts say.United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    April 5 Alaska Air Group Inc's plan to buy Virgin America Inc makes the company a more attractive partner to Asian airlines looking for extra revenue from connecting passengers to flights within the United States, industry executives and experts say.Airlines in Asia could get a lift from Alaska-Virgin mergerUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   Alaska Air Group Inc's  plan to buy Virgin America Inc  makes the company a more attractive partner to Asian airlines looking for extra revenue from connecting passengers to flights within the United States, industry executives and experts say.United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.     
HAL,After rally, earnings gloom takes hold on Wall StreetUS files lawsuit to block merger of Halliburton and Baker HughesUS sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.   US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  WASHINGTON, April 6 The U.S. Justice Department said on Wednesday that it filed a lawsuit aimed at stopping Halliburton from merging with Baker Hughes, a deal that would combine the No. 2 and No. 3 oil services companies.US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.    US files lawsuit to block merger of Halliburton and Baker HughesUS sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.   US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  WASHINGTON, April 6 The U.S. Justice Department said on Wednesday that it filed a lawsuit aimed at stopping Halliburton from merging with Baker Hughes, a deal that would combine the No. 2 and No. 3 oil services companies.US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.   Wall Street fell sharply on Tuesday as investors took gains off the table following a recent rally and ahead of an upcoming quarterly reporting season that is expected to reveal sharply lower earnings. | US files lawsuit to block merger of Halliburton and Baker HughesUS sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.   US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  WASHINGTON, April 6 The U.S. Justice Department said on Wednesday that it filed a lawsuit aimed at stopping Halliburton from merging with Baker Hughes, a deal that would combine the No. 2 and No. 3 oil services companies.US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.   VideoUS files lawsuit to block merger of Halliburton and Baker HughesUS sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.   US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  WASHINGTON, April 6 The U.S. Justice Department said on Wednesday that it filed a lawsuit aimed at stopping Halliburton from merging with Baker Hughes, a deal that would combine the No. 2 and No. 3 oil services companies.US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.    US files lawsuit to block merger of Halliburton and Baker HughesUS sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.   US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  WASHINGTON, April 6 The U.S. Justice Department said on Wednesday that it filed a lawsuit aimed at stopping Halliburton from merging with Baker Hughes, a deal that would combine the No. 2 and No. 3 oil services companies.US sues to block Halliburton-Baker Hughes deal, says anti-competitiveUPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.  UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector. WASHINGTON/HOUSTON The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.UPDATE 4-US sues to block Halliburton-Baker Hughes deal, says anti-competitive WASHINGTON/HOUSTON, April 6 The U.S. government filed a lawsuit on Wednesday to stop  Halliburton Co  from buying Baker Hughes Inc, arguing the combination of the No. 2 and No. 3 oil services companies would lead to higher prices in the sector.    
IBM,FEATURE-Golf-Augusta National masters art of minimal sponsorshipAugusta National masters art of minimal sponsorshipU.S. companies use social media to denounce laws seen as anti-gay NEW YORK, April 6 U.S. companies took to social media on Wednesday to denounce new laws enacted by southern states that target the lesbian, gay, bisexual and transgender (LGBT) community.  U.S. companies use social media to denounce laws seen as anti-gay NEW YORK, April 6 U.S. companies took to social media on Wednesday to denounce new laws enacted by southern states that target the lesbian, gay, bisexual and transgender (LGBT) community. AUGUSTA, Georgia Sports sponsorship deals, even multi-million dollar ones, follow a pretty basic process. This applies nearly everywhere, but not at the Masters golf tournament.U.S. companies use social media to denounce laws seen as anti-gay NEW YORK, April 6 U.S. companies took to social media on Wednesday to denounce new laws enacted by southern states that target the lesbian, gay, bisexual and transgender (LGBT) community.   Augusta National masters art of minimal sponsorshipU.S. companies use social media to denounce laws seen as anti-gay NEW YORK, April 6 U.S. companies took to social media on Wednesday to denounce new laws enacted by southern states that target the lesbian, gay, bisexual and transgender (LGBT) community.  U.S. companies use social media to denounce laws seen as anti-gay NEW YORK, April 6 U.S. companies took to social media on Wednesday to denounce new laws enacted by southern states that target the lesbian, gay, bisexual and transgender (LGBT) community. AUGUSTA, Georgia Sports sponsorship deals, even multi-million dollar ones, follow a pretty basic process. This applies nearly everywhere, but not at the Masters golf tournament.U.S. companies use social media to denounce laws seen as anti-gay NEW YORK, April 6 U.S. companies took to social media on Wednesday to denounce new laws enacted by southern states that target the lesbian, gay, bisexual and transgender (LGBT) community.  AUGUSTA, Georgia, April 6 Sports sponsorship deals, even multi-million dollar ones, follow a pretty basic process. This applies nearly everywhere, but not at the Masters golf tournament.Augusta National masters art of minimal sponsorshipU.S. companies use social media to denounce laws seen as anti-gay NEW YORK, April 6 U.S. companies took to social media on Wednesday to denounce new laws enacted by southern states that target the lesbian, gay, bisexual and transgender (LGBT) community.  U.S. companies use social media to denounce laws seen as anti-gay NEW YORK, April 6 U.S. companies took to social media on Wednesday to denounce new laws enacted by southern states that target the lesbian, gay, bisexual and transgender (LGBT) community. AUGUSTA, Georgia Sports sponsorship deals, even multi-million dollar ones, follow a pretty basic process. This applies nearly everywhere, but not at the Masters golf tournament.U.S. companies use social media to denounce laws seen as anti-gay NEW YORK, April 6 U.S. companies took to social media on Wednesday to denounce new laws enacted by southern states that target the lesbian, gay, bisexual and transgender (LGBT) community.   
JPM,MOVES-JPMorgan, BNY Mellon, North Highland, Aurelius, AXA IMJPMorgan's Dimon warns of economic trouble from Brexit NEW YORK, April 6 Jamie Dimon, CEO of JPMorgan Chase & Co warned on Wednesday that years of economic uncertainty would be the "best case" outcome from a decision by Britain to leave the European Union.  JPMorgan's Dimon warns of economic trouble from Brexit NEW YORK, April 6 Jamie Dimon, CEO of JPMorgan Chase & Co warned on Wednesday that years of economic uncertainty would be the "best case" outcome from a decision by Britain to leave the European Union. April 6 The following financial services industry appointments were announced on Wednesday. To inform us of other job changes, email moves@thomsonreuters.com.JPMorgan's Dimon warns of economic trouble from Brexit NEW YORK, April 6 Jamie Dimon, CEO of JPMorgan Chase & Co warned on Wednesday that years of economic uncertainty would be the "best case" outcome from a decision by Britain to leave the European Union.  
MKC,BRIEF-Premier Foods says has had constructive talks with McCormickPremier Foods says it held "constructive" talks with McCormickUPDATE 1-Premier Foods says it held constructive talks with McCormick April 6 Britain's Premier Foods Plc said it had held "constructive" talks with U.S. spice company McCormick & Co Inc and that it would meet its main institutional investors over the next few days.  UPDATE 1-Premier Foods says it held constructive talks with McCormick April 6 Britain's Premier Foods Plc said it had held "constructive" talks with U.S. spice company McCormick & Co Inc and that it would meet its main institutional investors over the next few days. April 6 Britain's Premier Foods Plc said it had held constructive talks with McCormick & Co Inc  and that it would meet its main institutional investors over the next few days.UPDATE 1-Premier Foods says it held constructive talks with McCormick April 6 Britain's Premier Foods Plc said it had held "constructive" talks with U.S. spice company McCormick & Co Inc and that it would meet its main institutional investors over the next few days.   Premier Foods says it held "constructive" talks with McCormickUPDATE 1-Premier Foods says it held constructive talks with McCormick April 6 Britain's Premier Foods Plc said it had held "constructive" talks with U.S. spice company McCormick & Co Inc and that it would meet its main institutional investors over the next few days.  UPDATE 1-Premier Foods says it held constructive talks with McCormick April 6 Britain's Premier Foods Plc said it had held "constructive" talks with U.S. spice company McCormick & Co Inc and that it would meet its main institutional investors over the next few days. April 6 Britain's Premier Foods Plc said it had held constructive talks with McCormick & Co Inc  and that it would meet its main institutional investors over the next few days.UPDATE 1-Premier Foods says it held constructive talks with McCormick April 6 Britain's Premier Foods Plc said it had held "constructive" talks with U.S. spice company McCormick & Co Inc and that it would meet its main institutional investors over the next few days.  * Providing an update following its announcement last week regarding revised proposed offer by mccormick & company, incPremier Foods says it held "constructive" talks with McCormickUPDATE 1-Premier Foods says it held constructive talks with McCormick April 6 Britain's Premier Foods Plc said it had held "constructive" talks with U.S. spice company McCormick & Co Inc and that it would meet its main institutional investors over the next few days.  UPDATE 1-Premier Foods says it held constructive talks with McCormick April 6 Britain's Premier Foods Plc said it had held "constructive" talks with U.S. spice company McCormick & Co Inc and that it would meet its main institutional investors over the next few days. April 6 Britain's Premier Foods Plc said it had held constructive talks with McCormick & Co Inc  and that it would meet its main institutional investors over the next few days.UPDATE 1-Premier Foods says it held constructive talks with McCormick April 6 Britain's Premier Foods Plc said it had held "constructive" talks with U.S. spice company McCormick & Co Inc and that it would meet its main institutional investors over the next few days.   
MCD,BRIEF-Andrew Mckenna to retire from Mcdonald's board of directorsMcDonald's Chairman Andrew McKenna to retire April 6 McDonald's Corp said its chairman of 12 years, Andrew McKenna, had decided he would not stand for re-election as a member of the company's board.  McDonald's Chairman Andrew McKenna to retire April 6 McDonald's Corp said its chairman of 12 years, Andrew McKenna, had decided he would not stand for re-election as a member of the company's board. * Andrew J. Mckenna to retire from Mcdonald's board of directorsMcDonald's Chairman Andrew McKenna to retire April 6 McDonald's Corp said its chairman of 12 years, Andrew McKenna, had decided he would not stand for re-election as a member of the company's board.  
MDT,Medtronic's wireless pacemaker wins U.S FDA nodMedtronic's wireless pacemaker wins FDA nod Medtronic Plc's wireless pacemaker was approved in the United states on Wednesday, making it the first pacemaker that does not need wired leads to correct slow heart rate.  Medtronic's wireless pacemaker wins FDA nod Medtronic Plc's wireless pacemaker was approved in the United states on Wednesday, making it the first pacemaker that does not need wired leads to correct slow heart rate. April 6 Medtronic Plc's wireless pacemaker was approved in the United states on Wednesday, making it the first pacemaker that does not need wired leads to correct slow heart rate.Medtronic's wireless pacemaker wins FDA nod Medtronic Plc's wireless pacemaker was approved in the United states on Wednesday, making it the first pacemaker that does not need wired leads to correct slow heart rate.  
MON,Monsanto sales fall on lower seed prices, strong dollarUPDATE 3-Monsanto cools on large-scale M&A; outlook, profit falls * Reiterates 2016 ongoing shr guidance of $4.40-$5.10   (New throughout, adds comment from analyst, updates share price, adds byline)  UPDATE 3-Monsanto cools on large-scale M&A; outlook, profit falls * Reiterates 2016 ongoing shr guidance of $4.40-$5.10   (New throughout, adds comment from analyst, updates share price, adds byline) April 6 Monsanto Co, the world's largest seed company, reported a 12.8 percent fall in quarterly sales, hurt by steep discounting on its seeds and a stronger dollar.UPDATE 3-Monsanto cools on large-scale M&A; outlook, profit falls * Reiterates 2016 ongoing shr guidance of $4.40-$5.10   (New throughout, adds comment from analyst, updates share price, adds byline)  
MS,Morgan Stanley aims to double custom loans for wealthy clients April 6 When a founder of a tech startup wants to buy a home but has all his money parked in illiquid stock, or a pro-athlete wants to buy a Porsche but has not yet received his guaranteed payout, Morgan Stanley wants to be the lender they turn to. 
NFLX,UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pct BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said. 
NOC,BRIEF-Northrop Grumman says submitted proposal to U.S. Air Force for next-generation GPS III program * says submitted proposal to U.S. Air Force for next-generation GPS III program  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom; +1 646 223 8780) 
PFE,Pfizer beats hundreds of lawsuits alleging Zoloft birth defectsDemocratic White House hopefuls cheer end of Pfizer, Allergan dealDemocratic White House hopefuls cheer end of Pfizer, Allergan dealBiotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's  $160 billion merger with Ireland-based Allergan Plc .Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook        Democratic White House hopefuls cheer end of Pfizer, Allergan dealBiotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's  $160 billion merger with Ireland-based Allergan Plc .Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       April 6 Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's $160 billion merger with Ireland-based Allergan Plc.Democratic White House hopefuls cheer end of Pfizer, Allergan dealBiotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's  $160 billion merger with Ireland-based Allergan Plc .Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook         Democratic White House hopefuls cheer end of Pfizer, Allergan dealDemocratic White House hopefuls cheer end of Pfizer, Allergan dealBiotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's  $160 billion merger with Ireland-based Allergan Plc .Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook        Democratic White House hopefuls cheer end of Pfizer, Allergan dealBiotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's  $160 billion merger with Ireland-based Allergan Plc .Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       April 6 Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's $160 billion merger with Ireland-based Allergan Plc.Democratic White House hopefuls cheer end of Pfizer, Allergan dealBiotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's  $160 billion merger with Ireland-based Allergan Plc .Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook        A federal judge in Philadelphia dismissed more than 300 lawsuits against Pfizer Inc alleging that its antidepressant Zoloft caused birth defects in children born to women who took the drug while pregnant.Democratic White House hopefuls cheer end of Pfizer, Allergan dealDemocratic White House hopefuls cheer end of Pfizer, Allergan dealBiotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's  $160 billion merger with Ireland-based Allergan Plc .Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook        Democratic White House hopefuls cheer end of Pfizer, Allergan dealBiotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's  $160 billion merger with Ireland-based Allergan Plc .Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       April 6 Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's $160 billion merger with Ireland-based Allergan Plc.Democratic White House hopefuls cheer end of Pfizer, Allergan dealBiotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook       Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U.S. drugmaker Pfizer Inc's  $160 billion merger with Ireland-based Allergan Plc .Biotech shares rally as Pfizer-Allergan deal collapsesUS STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook      US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     NEW YORK, April 6 The collapse of one pharmaceutical mega-merger could beget many smaller deals - at least that is the hope of biotech investors.US STOCKS-Wall St pushed higher by healthcare, energy stocksUPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook     UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    * Indexes up: Dow 0.39 pct, S&P; 0.65 pct, Nasdaq 1.02 pct   (Updates to early afternoon)UPDATE 3-Pfizer, Allergan scrap $160 bln deal after U.S. tax rule changeMega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook    Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   April 6 U.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes.Mega-deal collapse a second-quarter wake-up for merger-arb hedge fundsUS STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook   US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  LONDON Hedge funds which bet on mergers and acquisitions were hurt by the collapse of a $160 billion tie-up between pharmaceutical companies Pfizer  and Allergan  - although the effects could have been even worse.US STOCKS-Wall St rises with healthcare; oil ralliesBRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook  BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook * Indexes up: Dow 0.2 pct, S&P; 0.5 pct, Nasdaq 1 pct   (Updates to after Fed minutes)BRIEF-Moody's affirms Pfizer's A1/Prime-1 ratings * Moody's affirms Pfizer's A1/Prime-1 ratings; Stable outlook         
PHM,BRIEF-Former chairman of Pulte Homes Bill Pulte on CNBC: President Ryan Marshall and COO Harmon Smith could be good CEO candidatesBRIEF-Bill Pulte, grandson of PulteGroup founder, says President Ryan Marshall,COO Harmon Smith could be good CEO candidates - CNBC * Bill Pulte, grandson of PulteGroup founder, says former CEO James Grosfeld has more experience in homebuilding industry than other board members - CNBC  BRIEF-Bill Pulte, grandson of PulteGroup founder, says President Ryan Marshall,COO Harmon Smith could be good CEO candidates - CNBC * Bill Pulte, grandson of PulteGroup founder, says former CEO James Grosfeld has more experience in homebuilding industry than other board members - CNBC * Former chairman of Pulte Homes Bill Pulte on CNBC: current board member and former PulteGroup CEO James Grosfeld has more experience in homebuilding industry than other members on boardBRIEF-Bill Pulte, grandson of PulteGroup founder, says President Ryan Marshall,COO Harmon Smith could be good CEO candidates - CNBC * Bill Pulte, grandson of PulteGroup founder, says former CEO James Grosfeld has more experience in homebuilding industry than other board members - CNBC  
BK,MOVES-BNY Mellon names Piers Murray COO of markets business April 6 BNY Mellon appointed Piers Murray as chief operating officer to its markets business. 
UAL,Airlines in Asia could get a lift from Alaska-Virgin mergerAirlines in Asia could get a lift from Alaska-Virgin mergerBRIEF-United's pilots picket headquarters of activist investorsUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   * United Airlines pilots picket Boston headquarters of activist investors that are attempting to shake up the company's board - union  Further company coverage:    (Reporting By Jeffrey Dastin)United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.     BRIEF-United's pilots picket headquarters of activist investorsUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   * United Airlines pilots picket Boston headquarters of activist investors that are attempting to shake up the company's board - union  Further company coverage:    (Reporting By Jeffrey Dastin)United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    Alaska Air Group Inc's  plan to buy Virgin America Inc  makes the company a more attractive partner to Asian airlines looking for extra revenue from connecting passengers to flights within the United States, industry executives and experts say.BRIEF-United's pilots picket headquarters of activist investorsUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   * United Airlines pilots picket Boston headquarters of activist investors that are attempting to shake up the company's board - union  Further company coverage:    (Reporting By Jeffrey Dastin)United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.      Airlines in Asia could get a lift from Alaska-Virgin mergerBRIEF-United's pilots picket headquarters of activist investorsUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   * United Airlines pilots picket Boston headquarters of activist investors that are attempting to shake up the company's board - union  Further company coverage:    (Reporting By Jeffrey Dastin)United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.     BRIEF-United's pilots picket headquarters of activist investorsUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   * United Airlines pilots picket Boston headquarters of activist investors that are attempting to shake up the company's board - union  Further company coverage:    (Reporting By Jeffrey Dastin)United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    Alaska Air Group Inc's  plan to buy Virgin America Inc  makes the company a more attractive partner to Asian airlines looking for extra revenue from connecting passengers to flights within the United States, industry executives and experts say.BRIEF-United's pilots picket headquarters of activist investorsUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   * United Airlines pilots picket Boston headquarters of activist investors that are attempting to shake up the company's board - union  Further company coverage:    (Reporting By Jeffrey Dastin)United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.     April 5 Alaska Air Group Inc's plan to buy Virgin America Inc makes the company a more attractive partner to Asian airlines looking for extra revenue from connecting passengers to flights within the United States, industry executives and experts say.Airlines in Asia could get a lift from Alaska-Virgin mergerBRIEF-United's pilots picket headquarters of activist investorsUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   * United Airlines pilots picket Boston headquarters of activist investors that are attempting to shake up the company's board - union  Further company coverage:    (Reporting By Jeffrey Dastin)United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.     BRIEF-United's pilots picket headquarters of activist investorsUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   * United Airlines pilots picket Boston headquarters of activist investors that are attempting to shake up the company's board - union  Further company coverage:    (Reporting By Jeffrey Dastin)United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    Alaska Air Group Inc's  plan to buy Virgin America Inc  makes the company a more attractive partner to Asian airlines looking for extra revenue from connecting passengers to flights within the United States, industry executives and experts say.BRIEF-United's pilots picket headquarters of activist investorsUnited drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.    United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   * United Airlines pilots picket Boston headquarters of activist investors that are attempting to shake up the company's board - union  Further company coverage:    (Reporting By Jeffrey Dastin)United drops plan to acquire Delta's Newark landing slots -U.S. JusticeUPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.   UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  WASHINGTON, April 6 United Continental Holdings Inc has dropped its plan to acquire 24 take-off and landing slots at Newark Liberty International Airport from Delta Air Lines Inc, the U.S. Justice Department said on Wednesday.UPDATE 2-United drops plan to acquire Delta's Newark landing slotsUnited drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.  United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers. WASHINGTON/NEW YORK, April 6 The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.United drops plan to acquire Delta's Newark landing slots WASHINGTON/NEW YORK The U.S. Justice Department said on Wednesday that it dropped a lawsuit against United Continental Holdings Inc and Delta Air Lines Inc  after they abandoned a deal over landing slots in the New York area, which the department had warned threatened consumers.      
VZ,Verizon to buy 24.5 pct stake in AwesomenessTVBRIEF-Verizon to buy about 24.5 pct stake in AwesomenessTVUPDATE 1-Verizon to buy 24.5 pct stake in AwesomenessTV April 6 Verizon Communications Inc said it agreed to buy a 24.5 percent stake in AwesomenessTV, whose YouTube channels are among the most popular on the video site, for about $160 million.  UPDATE 1-Verizon to buy 24.5 pct stake in AwesomenessTV April 6 Verizon Communications Inc said it agreed to buy a 24.5 percent stake in AwesomenessTV, whose YouTube channels are among the most popular on the video site, for about $160 million. * Verizon, Dreamworks animation, Hearst and awesomenesstv to redefine premium mobile videoUPDATE 1-Verizon to buy 24.5 pct stake in AwesomenessTV April 6 Verizon Communications Inc said it agreed to buy a 24.5 percent stake in AwesomenessTV, whose YouTube channels are among the most popular on the video site, for about $160 million.   BRIEF-Verizon to buy about 24.5 pct stake in AwesomenessTVUPDATE 1-Verizon to buy 24.5 pct stake in AwesomenessTV April 6 Verizon Communications Inc said it agreed to buy a 24.5 percent stake in AwesomenessTV, whose YouTube channels are among the most popular on the video site, for about $160 million.  UPDATE 1-Verizon to buy 24.5 pct stake in AwesomenessTV April 6 Verizon Communications Inc said it agreed to buy a 24.5 percent stake in AwesomenessTV, whose YouTube channels are among the most popular on the video site, for about $160 million. * Verizon, Dreamworks animation, Hearst and awesomenesstv to redefine premium mobile videoUPDATE 1-Verizon to buy 24.5 pct stake in AwesomenessTV April 6 Verizon Communications Inc said it agreed to buy a 24.5 percent stake in AwesomenessTV, whose YouTube channels are among the most popular on the video site, for about $160 million.  April 6 Verizon Communications Inc said it agreed to buy a 24.5 percent stake in AwesomenessTV and create a new short-form mobile video service as part of the deal.BRIEF-Verizon to buy about 24.5 pct stake in AwesomenessTVUPDATE 1-Verizon to buy 24.5 pct stake in AwesomenessTV April 6 Verizon Communications Inc said it agreed to buy a 24.5 percent stake in AwesomenessTV, whose YouTube channels are among the most popular on the video site, for about $160 million.  UPDATE 1-Verizon to buy 24.5 pct stake in AwesomenessTV April 6 Verizon Communications Inc said it agreed to buy a 24.5 percent stake in AwesomenessTV, whose YouTube channels are among the most popular on the video site, for about $160 million. * Verizon, Dreamworks animation, Hearst and awesomenesstv to redefine premium mobile videoUPDATE 1-Verizon to buy 24.5 pct stake in AwesomenessTV April 6 Verizon Communications Inc said it agreed to buy a 24.5 percent stake in AwesomenessTV, whose YouTube channels are among the most popular on the video site, for about $160 million.   
WFC,CORRECTED-Wells Fargo supports 'best-interest' standard, is reviewing new rule NEW YORK, April 6 Wells Fargo & Co said it supported a "best-interest" standard for wealth management clients and was reviewing a new rule detailed by the U.S. Department of Labor on Wednesday. 
WMB,Williams sues Energy Transfer over preferred share offeringUPDATE 3-Williams sues ETE and CEO Warren over share offering April 6 Williams Companies Inc sued Energy Transfer Equity LP and its Chief Executive Kelcy Warren on Wednesday, claiming they violated the U.S. pipeline companies' merger agreement by making a private preferred share offering to ETE's top investors.  UPDATE 3-Williams sues ETE and CEO Warren over share offering April 6 Williams Companies Inc sued Energy Transfer Equity LP and its Chief Executive Kelcy Warren on Wednesday, claiming they violated the U.S. pipeline companies' merger agreement by making a private preferred share offering to ETE's top investors. April 6 Williams Companies Inc has sued Energy Transfer Equity LP to block a private preferred share offering disclosed last month, saying it was a breach of their merger agreement.UPDATE 3-Williams sues ETE and CEO Warren over share offering April 6 Williams Companies Inc sued Energy Transfer Equity LP and its Chief Executive Kelcy Warren on Wednesday, claiming they violated the U.S. pipeline companies' merger agreement by making a private preferred share offering to ETE's top investors.  
YHOO,BRIEF-Yahoo estimates that revenue will drop close to 15 pct, earnings by over 20 pct in 2016-RecodeYahoo expects 2016 revenue to drop about 15 pct - Re/codeUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pctHedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.    UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pctHedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   April 6 Yahoo Inc estimates revenue to drop nearly 15 percent and earnings to fall by over 20 percent in 2016, Re/code reported on Wednesday.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pctHedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.     Yahoo expects 2016 revenue to drop about 15 pct - Re/codeUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pctHedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.    UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pctHedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   April 6 Yahoo Inc estimates revenue to drop nearly 15 percent and earnings to fall by over 20 percent in 2016, Re/code reported on Wednesday.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pctHedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.    * Yahoo is estimating that revenue is dropping close to 15 percent and earnings by over 20 percent in 2016 - RecodeYahoo expects 2016 revenue to drop about 15 pct - Re/codeUPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pctHedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.    UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pctHedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   April 6 Yahoo Inc estimates revenue to drop nearly 15 percent and earnings to fall by over 20 percent in 2016, Re/code reported on Wednesday.UPDATE 1-Hedge fund Tiger Global down 21 pct; Viking off 8 pctHedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.   Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  BOSTON, April 6 Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.Hedge fund Tiger Global down 21 percent; Viking off 8 percentUPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.  UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document. BOSTON Hedge fund Tiger Global Management, known for making big bets on technology companies, slipped modestly in March, leaving it down 21 percent for the first three months of the year, an investor in the fund said.UPDATE 1-Yahoo expects 2016 revenue to drop about 15 pct -Re/code April 6 Yahoo Inc expects a sharp decline in both its revenue and earnings this year compared with 2015, with revenue seen falling nearly 15 percent and earnings over 20 percent, Re/code reported on Wednesday, citing a Yahoo document.     
